Previously, we have shown that systemically administered radiolabeled interleukin la (IL-la) accumulates preferen tially in inflammatory foci in mice. Since inflammation is characterized by influx of leukocytes, which represent IL-1 receptor (IL-1R) positive cells, radiolabeled IL-1 may spe cifically localize in inflammation by binding to its receptors on infiltrated leukocytes. This hypothesis was tested in a se ries of studies in mice with acute focal inflammations. Evi dence for specific IL-l-IL-lR interaction in induced inflam mation was found: microscopic autoradiography revealed that 125I-IL-la localized at the site of inflammatory cells with time; 125I-myoglobin, a similar-sized protein with no known interactions in vivo, was not retained in the inflam mation. Furthermore, the uptake 125I-IL-la in inflamma tory tissue was significantly lower in neutropenic mice than in immunocompetent mice (0.05 ±0.004 vs. 0.65 ±0.06% ID/g at 48 h after injection, P < 0.0007). Moreover, the uptake of *25I-IL-la at the inflammatory site could be blocked with the anti-IL-lR type II antibody 4E2. At 48 h after injection, the uptake with and without blocking the type IIIL-1R was 0.13±0.01 and 0.65±0.05% ID/g, respectively (P < 0.0001). These in vivo studies provide evidence that systemically ad ministered radiolabeled IL-la localizes in inflammatory tis sue by specific receptor binding, predominantly by binding to the type IIIL-1R. (X Clin.
Introduction
IL-1 is a 17-kD protein, produced by monocytes as a response to endotoxin. Two forms of IL-1, IL-la and IL-lß, have been discovered, binding to two types of receptors on a wide variety of cells. The type I IL-1 receptor (IL-1R), a 80-kD glycopro tein, is found on T cells, fibroblasts, hepatocytes, and endothe-liai cells, whereas B cells, macrophages, monocytes, and neu trophils express the 68-kD type II IL-1R (1). IL-1 binds to both receptors with affinity in the picomolar range (2) .
Since infection and inflammation are characterized by in flux of predominantly IL-1R positive leukocytes, systemically administered IL-1 may preferentially localize in inflammatory tissue by means of specific receptor binding. Recently, local ization of radiolabeled IL-la in Staphylococcus aureus-induced infections in mice was demonstrated (3) . It cleared rapidly from noninflamed tissues,
Receptor binding of IL-1 to murine leukocytes has been well characterized both in vitro and ex vivo (2 ,4, 5) . However, in vivo in mice, receptor binding has not been demonstrated directly but only indirectly via inhibition of IL-l-induced bio logic activity by blockade of type I IL-lRs (6) (7) (8) (9) (10) . In vivo bind ing to type II IL-lRs could not be shown due to lack of effect of type II IL-1R blockade on biologic activity (10) . The present paper describes a series of studies conducted to vali date the hypothesis of specific receptor binding of IL-la in inflammation in mice. Binding of systemically administered IL-la to type I as well as type II IL-'lRs was investigated by antibody-blocking studies. Our studies demonstrate localiza tion of IL-la in inflammatory tissue by specific binding to type II IL-lRs on locally present infiltrated leukocytes,
Methods
A4ice. Female Swiss mice weighing 20-25 g (Harlan Netherlands B.V., Zeist, The Netherlands) were kept in cages (5-15 mice per cage) and fed standard laboratory chow and water ad libitum.
Reagents. Human recombinant IL-la (specific activity of 3 X 108 U/mg) was kindly provided by Dr. P. Lomedico (Hoffman-La Roche, Nutley, NJ). Myoglobin was purchased from Sigma Chemical Co. (St. Louis, MO). The anti-IL-lR type I antibody (35F5) and the anti-IL-1 R type II antibody (4E2) (both monoclonal rat IgG) were prepared at Hoffmann-LaRoche.
Radioiodination. IL-la and IL-lß were radiolabeled using the iodogen method (11) . In brief, for microscopic autoradiography studies, 10 jjLg IL-la (0.68 mg/ml) in 10 (jlI 0.5 M and 80 |jlI 50 mM phosphate buffer, pH 7.2, and 111 MBq Nal25I (Amersham International, Amer sham, UK; specific activity of 570 GBq/mg) were added to glass tubes, precoated with 25 jjLg of l,3,4,6-tetrachloro-3a,6a-diphenylglucouril (Pierce, Rockford, IL). For all other studies, 3 |xg IL-la (0.68 mg/mi) or 3 jjug IL-lß (1 mg/ml) was labeled with 15-20 MBq Na125I. The reaction was allowed to proceed for 10 min at room temperature, after which the reaction mixture was eluted with 0.5% BSA in PBS on a Sephadex column (PD-10; Pharmacia, Uppsala, Sweden) to sep arate labeled IL-la and IL-lß from free 125I. The void fractions were pooled and sterilized through a 0 .2-(im filter.
Analogously, 10 juLg myoglobin (1 mg/ml), a protein with a molec ular mass (18 kD) similar to IL-la and IL-lß without any known in teractions in vivo, was labeled with Na125I.
The labeling efficiency of IL-la, IL-lß, and myoglobin was be tween 50 and 80%. For the microscopic autoradiography studies, 2970 van der Laken et al.
both IL-la and myoglobin were labeled with Na,25I at a specific activ ity of 8-12 MBq/fxg. The specific activity used in all other studies was 3-4 MBq/|xg.
The radiochemical purity of the radiolabeled proteins was deter mined by instant thin-layer chromatography (ITLC) on Gelman ITLC-SG strips (Gelman Laboratories, Ann Arbor, MI) with 0.1 M citrate, pH 5.0, as the solvent. The radiochemical purity of all radiola beled proteins was > 96% after removal of unbound iodine.
Typically, the receptor binding fraction and the dissociation con stant of radioiodinated IL-1 preparations were 70-95% and 5 X 10M1 mol/liter, respectively, as determined on the murine cell line EL-4-6.1, a variant subline of EL-4 thymoma cells (12) Ex vivo tissue biodistribution. Mice were killed under ether anes thesia by cervical dislocation at 5 min, Ï, 2, 6,12,24, and 48 h after in jection of 125I-IL-la, 125I-IL-lß, or free 125I. Blood samples, inflamed left calf muscle, right calf muscle, thymus, lungs, spleen, liver, and kidneys were collected. The dissected tissues were weighed and counted in the gamma counter. To correct for radioactive decay, in jection standards were counted simultaneously. The measured radio activity in tissues and samples was expressed as percentage of in jected radioactivity dose per gram of tissue (% ID/g).
Statistical analysis. All values are expressed as m eaniSEM . Sta tistical analysis was performed using the one-way ANOVA.
Results

The uptake o f 125f-IL-la in inflammation in the course o f time.
The blood clearance and uptake in inflammation of 12SI-I.L-la and free 1251 was determined in mice with S. aureus-induced in flammation at various time points (n = 5 for each preparation per time point) after intravenous injection of 0.4 MBq 120 ng of 125I-IL-la or 0.4 M Bq of free 125I. Despite rapid clearance from the blood, 125I-IL-la accumulated in the inflammation, reaching maximum values of uptake within 2 h after injection (Fig. 1 A ) . 2 h after injection, the uptake of 125I-IL-la in in flammation decreased. A significant level of l25I-IL-la was re tained in the inflammatory tissue up to 48 h after injection (0.8% ID/g). In contrast, lliI-LL-la levels in the blood continu ously decreased to a level < 0.05% ID/g at 48 h after injection. 12 h after injection, the uptake of 125I-IL-la in inflammation was significantly higher than the blood levels (P < 0.005). The retention of activity in inflammation with time was due to up take of 125I-IL-la and not of free 125I:free I25I rapidly cleared from the inflammation in a similar fashion as from the blood (Fig. 1 B) . To be able to study the specific receptor-binding mechanism oí 125I-IL-1 in inflammation, the following studies focused on the time span of 12-48 h after injection because of high background activity levels at early time points. Comparison of uptake of ml-ïL-la and ,25l-lL-lß in in flammation. The biodistribution of both 125I-IL-la and 125I-IL-lß was determined in mice with S. aureus-induced inflammations at various time points (n = 5 for each radiolabeled preparation per time point) after intravenous injection of 0.4 MBq 120 ng of the radiolabeled preparation. The uptake of l25I-IL-la in in flammation was higher than of 125I-IL-lß (Fig. 2) . At 48 h after injection, 0.76±0.11 % ID/g of I25I~IL-la was still found in the inflammation, while levels of 125l-IL-lß decreased to 0.15± 0.01% ID/g at 48 h after injection. From 12 h after injection onwards the uptake of 125I-IL-la at the site of inflammation was significantly higher than of 1251-IL-lß (P < 0.05). Due to the significantly higher uptake of 125I-IL-la in inflammation as compared with U5I-IL-lß, further studies exploring the recep tor-binding mechanism at the inflammatory site were per formed with IL-la.
Microscopic autoradiography. Microscopic autoradiogra phy was applied to study whether systemically administered radiolabeled IL-la localizes at the site of infiltrated leukocytes in induced inflammation in mice. As early as 2 h after injec tion, uptake of 125I-IL-la in the inflammation was observed. At this time point, most of 125I-IL-la, found in areas of cellular infiltration, was Localized around the blood vessels. The radio label was also found in the unaffected muscular tissue. With time, I25I-IL-la was retained within the cellular infiltration, while the uptake in the unaffected muscle tissue decreased. After 24 h, nearly all 125I-IL~la was clearly associated with the site of inflammatory cells, as demonstrated in Fig. 3,^4 and B.
In contrast, no specific retention of 125I-IL4a was found in the contralateral muscle (Fig. 3 C) . The size-matched control pro tein 125I-myoglobin did not localize at the site of the inflamma tory cells (Fig. 3 D) .
The above observations were analyzed quantitatively. The results are shown in Fig. 4 . As early as 2 h after injection, most l25I-IL-la was found in the area of the cellular infiltration at 2 h after injection. The number of grains in the contralateral muscle and in areas of unaffected muscular tissue in the in flammation decreased during the time course of the experi ment. Thus, with time, 125I4L4a migrated from the unaffected muscle tissue to the inflammatory cells within the inflamma tion. After 24 h, nearly all grains in the infection were found in 2972 van der Laken et a l the area of cellular infiltration. At all time points, the number of grains in the cellular infiltration was significantly higher than the number of grains in the adjacent unaffected muscle and the contralateral muscle (P < 0.0001). Furthermore, the uptake of 125I-IL-la in the area of the cellular infiltration was significantly higher than of 125I-myoglobin at 24 h after injec tion (P < 0.0001).
Comparison of biodistribution o fI25l-IL-la in immunocom petent and neutropenic mice. To study whether the presence of cellular infiltration is crucial to localization of radiolabeled IL-la in inflammation, effects of neutropenia were investi gated and compared with observations in immunocompetent mice. Zymosan, instead of S. aureus, was used for induction of inflammation in these studies to prevent mortality due to sep sis in neutropenic mice. Histology demonstrated that the mas sive infiltration of leukocytes, predominantly PMNs, as ob served in immunocompetent mice was absent in neutropenic mice (data not shown). The biodistribution of 125I-IL-la in im munocompetent (n = 25) and neutropenic mice (n = 25) , de termined at various times after intravenous injection of 0.4 MBq 120 ng of the radiolabeled preparation, was similar (Ta ble I). 125I4L-la rapidly cleared from most organs. However, one major difference was observed: l25I4 L 4 a was retained at the site of inflammation in immunocompetent mice, while vir tually no retention of l2iT-IL4a in the inflammation was found in neutropenic mice (Fig. 5) . At all time points, the uptake of i25I-IL-la at the site of inflammation was significantly higher in immunocompetent mice than in neutropenic mice (P < 0.001). Maximum differences were obtained at 48 h after injec tion; the uptake of 125I-IL-la in inflammation was > 12 times higher in immunocompetent mice compared with neutropenic mice, 0.65±0.06 and 0.05±0.004% ID/g, respectively. To ile saline before injection of l25I-IL-la. As depicted in Fig. 6 , mice with type IIL-1R blockade displayed significantly higher uptake of l25I4 L 4 a in the inflammation than the control group, i.e., 2.26±0.12 vs. 0.65±0.05% ID/g at 48 h after injec tion (P < 0.0001). In contrast, the uptake of I25I-IL-la at the site of inflammation in mice with blockade of type II IL-lRs (0.13±0.009) was significantly lower than the value obtained in control mice (P < 0.0001). A similar low uptake of 0.1.4± 0.009% ID/g in inflammation was found in mice with both type I and type IIIL-1R blockade. The l25I4L-la levels in the blood and all other organs were similar for all studied groups (data not shown).
Effect of in vivo blockade of IL-lRs on localization of 125I-IL-1 a in inflammation.
Discussion » This study confirms the hypothesis that systemically adminis tered radiolabeled IL-la localizes in acute inflammatory foci by specific receptor binding. As demonstrated by microscopic autoradiography, IL-la localized within the inflammation at the site of the infiltrated leukocytes, which were predomi- mulates in inflammatory tissue by means of binding to its re ceptors on infiltrated leukocytes. The IL-1R blockade studies showed that the binding of ra diolabeled IL-la to infiltrated leukocytes was mainly due to binding to type II IL-lRs. The inflammation uptake of IL-la was significantly lower in case of blockade of type II IL-lRs. Surprisingly, increased uptake of radiolabeled IL-la in the in flammation was found when type I IL-lRs were blocked. Blockade of type I IL-lRs, expressed on a wide range of cells in the body, may have increased levels of free IL-la, available for binding to type II IL-lRs, expressed on infiltrated neutro phils and monocytes in the inflammation. When both type I and type II IL-lRs were blocked, inflammation uptake of IL-la was as low as that found with type II IL-1R blockade only. This indicates that the increased uptake of IL-la in inflamma tory tissue (obtained by blockade of type I IL-lRs) could be completely inhibited by blockade of type II IL-lRs. Therefore, aspecific increased uptake of IL-la in inflammation in case of type IIL -1 R blockade could be ruled out. Binding to soluble type II IL-lRs, increased during various inflammatory condi tions (21) (22) (23) , could also be excluded since the used anti-type II antibody 4E2 also binds and neutralizes these receptors.
Although blockade of binding of radiolabeled IL-la to type II IL-lRs with the antibody 4E2 has been demonstrated in vitro on cell lines (24) , in vivo, blockade of type II IL-lRs did not affect particular studied biologic effects of IL-la (7, 10) . Since it is now generally accepted that the type II IL-1R acts as a decoy receptor for IL-1 (25-28), no direct effects of type IIIL -1 R blockade on IL-1 induced biologic activity are to be expected. Indirectly, type II IL-1R blockade may enhance ceptor-bound IL -1 (31) and a fast turnover of the receptor (2 h) (32) . However, these characteristics were observed in vitro us ing the Raji human B lymphoma cell line. In vivo, IL-1 binding to type II receptors on activated leukocytes in inflammatory tissue may be different. This study supports first indications that systemically ad ministered radiolabeled IL-la localizes in inflammation by specific receptor binding. The type II IL-1R appeared to be the predominant binding site in acute inflammation models. Actual binding of IL-la to type II IL-1R in inflammatory tis sue could be demonstrated. Future studies will focus on the in vivo behavior of IL-la and the correlation with IL-1R expres sion in various other inflammation models. effects of type IIIL -1 R blockade on IL-l-induced biologic ac tivity were not evaluated, but the inhibition of receptor bind ing of radiolabeled IL-la at the site of inflammation by type II IL-1R blockade could be shown in vivo.
The uptake of IL-lß in inflammation was lower than the uptake of IL-la. Apparently, lower amounts of IL-lß bound to IL-lRs in the inflammatory tissue. Since systemically ad ministered IL-1 appears to mainly bind to type II IL-lRs, these findings are in line with data obtained by Parker et al. (4) . They also tested the binding of human recombinant IL-la and IL-lß for the type II IL-1 R on murine PMNs and found a twoto threefold lower affinity for IL-lß as compared with IL-la. Opposite results have been reported for the binding of human recombinant IL-la and IL-1 ß to the human type IIIL -1R (29, 30) , indicating that species differences play a role in receptorbinding characteristics of IL-la and IL-lß.
Although the total amount of radiolabeled IL-la in the in flammation decreased with time, retention was still found at 48 h after injection. Most likely, as demonstrated by the micro scopic autoradiography results, IL-la accumulates in inflam matory tissue shortly after injection and migrates toward the binding sites on infiltrated leukocytes during the next 24 -48 h. Some IL-la molecules will bind easily accessible receptors early after injection and others reach binding sites several hours thereafter. After 24 h, radiolabeled IL-la, retained in the inflammation, could almost only be found in areas of cellu lar infiltration. In the meantime, most of the unbound and/or degraded IL-la is cleared from the tissue, resulting in a de creasing total amount of radiolabeled IL-la in the inflamma tion. Despite the latter, the uptake in areas of cellular infiltra tion even increased with time, which could be explained by the fact that these areas form the minority of the total inflamma tion. Since IL-la seemed to bind mainly to type II IL-lRs in the models of inflammation studied, these observations may be conflicting with data suggesting poor internalization of re-
